Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma

Table 1 Considerations in initiating systemic therapy over transarterial chemoembolization[26,44,53-55]

No.	Considerations
1	Tumor exceeds “the up to seven" criteria
2	Tumor(s) larger than 5cm
3	Contiguous multinodular tumors
4	Poorly differentiated or undifferentiated HCC
5	No objective response to 2 consecvutive TACE treatments

HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.

Table 2 Combination therapy trials

Trial therapies	Study name	Phase	Patient number or estimation	ORR	Median PFS	Median OS
Lenvatinib + TACE vs Lenvatinib[47]	LAUNCH	Phase 3	338	54.1% vs 25%	10.6 mo vs 6.4 mo	17.8 mo vs 11.5 mo
(cTACE or DEB-TACE) + durvalumab followed by durvalumab + placebo vs (DEB-TACE or cTACE) + durvalumab followed by durvalumab + bevacizumab vs (DEB-TACE or cTACE)[48]	EMERLD	Phase 3	600	In progress	In progress	In progress
Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE[49]	LEAP-012	Phase 3	950	In progress	In progress	In progress
Nivolumab + Ipilimumab + TACE vs Nivolumab + Placebo + TACE vs Placebo + Placebo + TACE[50]	Checkmate-74W	Phase 3	765	In progress	In progress	In progress
Brivanib + TACE vs Placebo + TACE[51]	BRISK-TA	Phase 3	502	48% vs 42%	8.4 mo vs 4.9 mo1	26.4 mo vs 26.1 mo
Oranitib + TACE vs Placebo + TACE[52]	ORIENTAL	Phase 3	889	Not reported	2.9 mo vs 2.5 mo1	31.1 mo vs 32.3 mo
Tremelimumab + TACE[53]		Phase 2	11	18%	7.4 mo1	13.6 mo

¹Reported as time to radiographic progression.

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; TACE: Transarterial chemoembolization.